DEA Ends cannabis rescheduling Hearing; Record Grows
DEA hearing ends after 11 days; opponents compile evidence on youth exposure, product variability and diversion as agencies consider cannabis rescheduling;
Cannabis news, weed news, marijuana news
DEA hearing ends after 11 days; opponents compile evidence on youth exposure, product variability and diversion as agencies consider cannabis rescheduling;
Nearly 4 million people on probation or parole face barriers to medical cannabis despite 47 state programs; some states now require individualized access
Acting AG won’t expand cannabis rescheduling; MA ballot initiative will appear in November; Fetterman urges legalization; NFL study reports athlete
DEA hearing on cannabis rescheduling draws seven opposition groups; FDA witness defends 252-page HHS analysis, two-part CAMU test, and 2023 recommendation.
Cannabis rescheduling prompts two companies to intervene in federal lawsuits; Congress files IBOGAINE Act; states update zoning and medical cannabis access.
Opponents present witnesses and evidence at DEA hearing on marijuana rescheduling, starting June 29 and running through July 15; DEA bars supporters and
DOJ reclassifies medical cannabis to Schedule III April 23, opening DEA registration, easing 280E tax limits, and changing Nevada research, sales, and
cannabis rescheduling hearing starts June 29; DEA named seven opposing parties and excluded rescheduling advocates. Judge Derek Julius presides through
In response to delays in the marijuana rescheduling process that began under the previous presidential administration, congressional researchers assert that…
Veterans returning from military service often face significant challenges, including anxiety, chronic pain, and post-traumatic stress disorder (PTSD). After serving…